Internal Medicine
RSSArticles
-
Cefepime and Enmetazobactam Injection (Exblifep)
The U.S. Food and Drug Administration has approved the combination of cefepime and enmetazobactam (FPE) for the treatment of complicated urinary tract infections. Cefepime-enmetazobactam was granted a priority review and a five-year marketing exclusivity as part of the Generating Antibiotic Incentive Now (GAIN) Act incentivizing development of new anti-infectives. FPE is distributed by Allecra Therapeutics SAS as Exblifep.
-
Comparing Early vs. Late-Onset MS
A recent retrospective study, combining data from a United Kingdom patient registry with a United Kingdom neuropathology tissue bank, showed that late-onset multiple sclerosis (MS), referring to disease onset after age 50 years, is linked with increased disability and quicker progression compared to MS onset at a younger age, and has distinct pathological features.
-
Timing of Biomarker Changes in Alzheimer’s Disease
In a longitudinal multicenter, nested case-control study of cognitive normal participants from China, the time courses of key Alzheimer’s disease biomarkers were identified during the 20 years preceding clinical diagnosis of sporadic Alzheimer’s disease.
-
Better Outcomes for Acute Stroke Patients Who Arrive Rapidly at Endovascular-Capable Centers
The SELECT2 trial was structured to identify which patients with large ischemic strokes would benefit from endovascular thrombectomy and analyzed the effect of direct arrival at a thrombectomy-capable center compared to transfer from a primary stroke center.
-
Meningococcal Disease Is on the Rise
The number of cases of infection with Neisseria meningitidis is increasing in the United States. The majority of presentations are with bacteremia; meningitis is infrequent.
-
Fat May Be the Healthiest Part of Dairy
There are numerous health benefits of dairy fat intake and dairy fat lacks the problems associated with dairy sugar and proteins.
-
Resmetirom Tablets (Rezdiffra)
The U.S. Food and Drug Administration has approved the first drug and first-in-class for the treatment of metabolic dysfunction-associated steatohepatitis (formerly known as nonalcoholic steatohepatitis). Resmetirom is a selective thyroid hormone receptor-beta partial agonist and was granted an accelerated approval. It is distributed by Madrigal Pharmaceuticals, Inc. as Rezdiffra.
-
Quality, not Quantity: Plant-Based Carbs Might Result in Less Weight Gain
This long-term prospective study found that adults on low-carbohydrate diets rich in plant-based and whole grain sources of protein and fat experienced significantly less weight gain than those on other types of low-carbohydrate diets.
-
Food as Medicine? Follow the Evidence
In this randomized, controlled study of more than 400 individuals with uncontrolled type 2 diabetes and food insecurity, an intensive intervention offering healthy groceries and educational efforts failed to significantly affect glycemic control but resulted in heightened engagement with preventive healthcare services in the intervention group compared to the control.
-
Can Bariatric Surgery Control Blood Pressure Long-Term?
A randomized trial comparing bariatric surgery to medical therapy in hypertensive obese patients has shown that bariatric surgery effectively lowers blood pressure over five years of follow-up.